
Journal of Medicinal Chemistry p. 686 - 694 (1995)
Update date:2022-08-04
Topics:
Faull, Alan W.
Brewster, Andrew G.
Brown, George R.
Smithers, Michael J.
Jackson, Ruth
The design, synthesis, and pharmacology of a new class of compounds possessing bith thromboxane receptor antagonist and thromboxane synthase inhibitory properties are described.Replacement of the phenol group of the known thromboxane antagonist series 4(Z)-6-<(4RS,5SR)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl>hex-4-enoic acid by a 3-pyridyl group led to a series of compounds, 5, which were potent thromboxane synthase inhibitors and weak thromboxane antagonists.Further modifications at the dioxane C2 position led to compounds, 7, which were potent dual-acting agents.In the case of compound 7w, the dual activity was shown to reside almost exclusively in the (-)-enantiomer, 7x.Following oral dosing to rats and dogs, 7x (3 mg/kg) displayed significant dual activity over a period of at least 8 h.
View MoreContact:+86-535-8888888
Address:No.161 Haishi Rd.
Zhejiang Golden-Shell Pharmaceutical Co.,Ltd.
Contact:+86-576-87501888 / 87501988
Address:No.89 Zhongxing Road. Li'ao, Yuhuan, Zhejiang, China
QINGDAO TAOSIGN INTERNATIONAL TRADE CO.,LIMITED
Contact:+86-0532-82683616
Address:RM1402, Doublestar Seacoase 7#, No. 5 Guizhou Road, Qingdao, Shandong, China
Chengdu Pukang Biotechnology Co., Ltd
Contact:+86-28-82550498
Address:No. 558 Rulin Road,Xinjin county,Chengdu city, China
Contact:86-21-57725962
Address:shanghai
Doi:10.1002/hlca.19930760709
(1993)Doi:10.1016/S0040-4039(00)60337-4
(1993)Doi:10.1007/BF00863826
(1992)Doi:10.1055/s-0033-1339690
(2013)Doi:10.1016/j.ejmech.2017.04.049
(2017)Doi:10.3390/molecules20046153
(2015)